Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02747797
Title Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors eresa Helsten, MD
Indications
Therapies
Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST